Table 1.
Cohort demographics and clinical characteristics.
| Myasthenic crisis (n = 15) | No myasthenic crisis (n = 43) | |
|---|---|---|
| Sex | ||
| Male, n (%) | 7 (46.7) | 21 (48.8) |
| Female, n (%) | 8 (53.3) | 22 (51.2) |
| Age | ||
| Age at diagnosis, years, mean (SD) | 56 (16.5) | 51 (17.2) |
| Early onset MG, n (%) | 6 (40.0%) | 16 (37.2%) |
| Late onset MG, n (%) | 9 (60.0%) | 27 (62.8%) |
| Number of MC per patient | ||
| 0 | - | 43 |
| 1 | 11 (73.3%) | - |
| 2 | 2 (13.3%) | - |
| 3 | 2 (13.3%) | - |
| AChR antibodies | ||
| Positive | 10 (66.7%)* | 28 (65.1%) |
| Negative for AChR, MuSK, LRP4 | 5 (33.3%) | 15 (34.9%) |
| Thymectomy | ||
| No, n (%) | 5 (33.3%) | 15 (34.9%) |
| Yes, n (%) | 10 (66.7%) | 28 (65.1%) |
| Thymus pathology | ||
| Thymoma, n (%) | 5 (50.0%) | 14 (50.0%) |
| Hyperplasia, n (%) | 2 (20.0%) | 5 (18.0%) |
| Unremarkable, n (%) | 3 (30.0%) | 8 (29.0%) |
| Unknown, n (%) | – | 1 (4.0%) |
*One MC patient was found positive for AChR and MuSK. As there were no appropriate AChR/MuSK-double positive controls, she was considered in the AChR+ group.